Checklist for NPCR and SEER Incidence – U.S. Cancer Statistics Public Use Database, 2005–2015 Analyses

• If a user-defined primary site variable was created (rather than using the Site recode ICD-O-3/WHO 2008 variable)—
  • Did you exclude leukemias and lymphomas (9590–9992)?
  • Did you consider excluding Kaposi sarcoma (9140) and mesothelioma (9050–9055)?¹
• If your analysis includes histology, and if appropriate for the cancer site, did you use the Diagnostic Confirmation variable to specify the analysis be limited to Microscopically confirmed cases?²
• If you are analyzing sex-specific cancers (such as prostate cancer or female breast cancer), did you limit the analysis to the appropriate sex to get the correct population denominator?³
• When reporting rates, have you included the label “per 100,000 persons,” “per 100,000 women,” or “per 100,000 men”?
• Have you included citations for the—
  • Percentage of United States population coverage provided by the database?
  • NPCR and SEER Incidence – U.S. Cancer Statistics 2005–2015 Public Use Research Database?⁴

References

¹See data dictionary Cdc-pdf[PDF-758KB] – Cautionary Notes section entitled Primary Site Variables.

²See data dictionary Cdc-pdf[PDF-758KB] – Diagnostic Confirmation variable descriptions.

³See data dictionary Cdc-pdf[PDF-758KB] – Sex variable description.

⁴See data dictionary Cdc-pdf[PDF-758KB] – Data Citation section.